You may have encountered the diagnosis “10q26 deletion syndrome” through an NIPT result or an ultrasound finding, and the unfamiliar terminology may feel overwhelming.
Here is the short answer first. This condition arises when the terminal “26” region of the long arm (q) of chromosome 10 is congenitally missing, and it is an extremely rare chromosomal disorder with roughly 100 cases reported worldwide. The core features are growth delay, developmental delay, distinctive facial characteristics, and genital abnormalities that are more common in males, though complications involving the heart or kidneys can also occur depending on how much of the chromosome is missing.
This article walks through the chromosomal change that causes the condition, how it differs from similarly named disorders (deletions at other regions of chromosome 10 and a disorder on chromosome 12), its symptoms, inheritance pattern, its relationship to prenatal diagnosis and NIPT, the path to a definitive diagnosis, and the outlook for treatment — all based on information from GARD, Orphanet, and peer-reviewed medical literature. Let’s go through it one step at a time.
💡 What you’ll learn in this article
- What chromosomal change causes 10q26 deletion syndrome
- How it differs from the similarly named 10q22 deletion and 12q14 deletion
- Why the severity of symptoms depends on how much of the chromosome is missing
- Inheritance patterns (de novo vs. familial) and what they mean for a future pregnancy
- Whether this condition is covered by prenatal diagnosis or NIPT
- Treatment approaches and family support options after diagnosis
1. What Is 10q26 Deletion Syndrome? (The Chromosomal Change Behind It)
This condition occurs when the terminal “26” region of the long arm (q) of chromosome 10 is congenitally missing. Medically, it is also known as “distal 10q deletion syndrome,” a name used interchangeably for the same condition.
According to GARD (Genetic and Rare Diseases Information Center), run by the U.S. National Institutes of Health, the size of the deleted region varies from case to case, ranging from 3.5 to 17 megabases (Mb) — there is no fixed size, and individual variation is substantial. MedlinePlus, run by the U.S. National Library of Medicine, describes the condition as an extremely rare chromosomal disorder with “at least 100 cases reported in the medical literature to date.” Europe’s rare disease database Orphanet (distal 10q deletion syndrome) also lists it as an extremely rare disorder.
A case report and literature review published in 2016 compiled more than 110 reported cases worldwide, and identified FGFR2, DOCK1, and CTBP2 as genes closely linked to the symptoms. Which genes fall within the deleted region differs from person to person, which is why the combination of symptoms varies so much between patients.
2. How It Differs From Similarly Named Disorders (Other Regions of Chromosome 10 and Chromosome 12)
Even though disorders may be lumped together as “an abnormality of chromosome 10,” a different deletion location means different genes are involved and entirely different symptoms appear. Here is how this condition compares with similarly named disorders covered elsewhere on our site.
| Condition | Chromosomal Location | Key Genes Involved | Core Features |
|---|---|---|---|
| 10q26 deletion syndrome (this article) | Chromosome 10, terminal long arm (q26) | FGFR2, DOCK1, CTBP2, and others | Growth delay, developmental delay, genital abnormalities; cardiac/renal complications depending on extent |
| 10q22-3q23-2 deletion syndrome | Chromosome 10, near the middle of the long arm (q22-q23) | Genes in a different region from this article | Different symptom combination (see linked article) |
| 12q14 microdeletion syndrome | Chromosome 12 (a different chromosome) | HMGA2 and others | Primarily short stature and skeletal features (see linked article) |
Even when the underlying mechanism is the same — “part of a chromosome is missing” — a different location means different genes are affected and the central symptoms change. For more detail on each condition, please see our articles on 10q22-3q23-2 deletion syndrome and 12q14 microdeletion syndrome.
We also have an article on 15q26-qter deletion syndrome, which shares the same underlying mechanism of a “terminal deletion,” even though it involves a different chromosome. It can be a useful reference for understanding what a terminal deletion means.
3. Main Symptoms (Features Vary With the Extent of the Deletion)
Because the genes involved change depending on where the deletion begins, both the combination and severity of symptoms differ from person to person. A clinical comparison study published in 2015 showed that symptom tendencies differ depending on the size of the deletion.
| Symptom / Feature | What Has Been Reported |
|---|---|
| Prenatal and postnatal growth delay | A core feature, seen as intrauterine growth restriction (IUGR) or poor weight gain after birth |
| Developmental delay / intellectual disability | Mostly mild to moderate; often first noticed as delayed speech or motor development |
| Distinctive facial features | A broad nasal bridge, an upturned nasal tip, a small jaw (micrognathia), low-set ears, and microcephaly |
| Genital abnormalities (more common in males) | Hypospadias, undescended testes, micropenis; considered a prominent feature of deletions involving the more distal region (10q26.2) |
| Kidney and urinary tract abnormalities | Reported more often with deletions that extend into the more proximal region (10q26.12-10q26.13) |
| Congenital heart disease | Atrial septal defect and patent ductus arteriosus have been reported |
| Hearing loss | Linked to the WDR11, HMX2, and HMX3 genes |
| Behavioral features | Attention-deficit/hyperactivity disorder (ADHD), impulsivity, and autistic tendencies |
What matters here is that not every symptom appears in every patient. The 2015 study mentioned above found that smaller deletions limited to the more distal region tend to center on genital abnormalities and developmental delay, while larger deletions that also include the more proximal region (10q26.12-13) are more likely to add kidney and urinary tract abnormalities. Please review the extent of the deletion noted in the diagnosis together with your child’s physician.
4. Cause and Inheritance Pattern (De Novo vs. Familial)
Most cases arise from a spontaneous (de novo) change, and the implications for a future child depend on the family’s specific situation. The condition follows an autosomal dominant pattern, meaning a deletion in just one of the two copies of chromosome 10 is enough to cause symptoms.
De Novo (Spontaneous) Cases
This deletion can arise by chance during the formation of sperm or eggs, or during cell division shortly after fertilization. In the 2016 case report mentioned earlier, both reported cases had parents with normal chromosomes, confirming that the change was de novo. It is not caused by diet or lifestyle during pregnancy. In clinic, I always tell parents there is no reason to blame themselves.
Familial Cases
In rare cases, one parent unknowingly carries a balanced chromosomal translocation — a rearrangement where the total genetic material is unchanged but its order is shuffled — without any symptoms, and that rearrangement becomes unbalanced in the next generation, appearing as a deletion. In this scenario, the theoretical chance of passing the deletion on to a future child is about 50%. Chromosomal testing of both parents is useful for accurately understanding a family’s inheritance pattern.
If you are concerned about the implications for a future child, genetic counseling with a clinical geneticist or certified genetic counselor is worth considering. Even knowing the parents’ test results can make it easier to plan for a future pregnancy.
5. Relationship to Prenatal Diagnosis and NIPT
A terminal deletion at 10q26 is not covered by standard NIPT, and even among expanded NIPT panels that screen for microdeletions, very few providers specifically name this region as covered.
Standard NIPT mainly screens for numerical chromosomal changes — trisomy 21, 18, and 13. Some expanded panels also cover relatively common microdeletions, such as 22q11.2 deletion syndrome, but as noted above, the 10q26 region has only around 100 reported cases worldwide, so most testing providers do not include it in their standard scope. Coverage varies from company to company, so it is worth confirming in advance exactly what the plan you are considering screens for.
Here at Hiro Clinic NIPT, we sometimes hear from patients who say, “An ultrasound showed growth delay or a heart abnormality, and now I’m worried it might be a chromosomal change.” The first thing to know is that NIPT is only a non-definitive screening test.
The NIPT guidelines issued by the Japan Society of Obstetrics and Gynecology also state that NIPT results remain within the scope of screening (non-definitive) testing. A definitive diagnosis requires an invasive test such as amniocentesis. If growth restriction or a heart abnormality is noted on ultrasound, the cause is not necessarily a chromosomal abnormality — other factors are possible as well. Rather than jumping to conclusions, it helps to work through the findings step by step with a specialist.
6. The Path to a Definitive Diagnosis
Chromosomal microarray analysis (CMA), a detailed genetic test, plays the central role in reaching a definitive diagnosis.
Chromosomal Microarray Analysis (CMA)
This test can detect deletions as small as a few kilobases to a few megabases — changes too small for conventional microscope-based chromosome analysis (G-banding) to catch. It reveals exactly where a deletion begins and ends, and whether it includes genes such as FGFR2 or DOCK1. For more on the relationship between amniocentesis and microarray testing, see our article on amniocentesis microarray testing.
Parental Testing
Testing the blood of both parents can determine whether the deletion is de novo or was passed down through a balanced translocation within the family. This is also important information when thinking about the outlook for a future child.
Postnatal Evaluation
After diagnosis, doctors build a full picture of the child’s condition by combining growth chart tracking, echocardiography to check for heart disease, renal ultrasound, hearing tests, and developmental assessments.
7. Treatment and Support
There is no cure that restores the missing part of the chromosome, but multidisciplinary support can help promote a child’s growth and development.
- Developmental therapy: Physical therapy (PT), occupational therapy (OT), and speech-language therapy (ST) support the development of motor skills, language, and daily living skills.
- Cardiac and renal management: Pediatric cardiologists and nephrologists work together to decide, based on severity, whether observation or active treatment is needed.
- Hearing and vision care: Hearing aids and ophthalmologic correction address hearing loss, strabismus, and refractive errors.
- Behavioral support: Psychological therapy and therapeutic support are offered for ADHD and impulsivity.
Because the combination and severity of symptoms differ so much from person to person, there is no single fixed course this condition always follows. Working with your child’s pediatrician, relevant specialists, and therapy staff, you will build a support plan tailored to your child, one step at a time.
8. Outlook and Prognosis
Because so few cases have been reported, it is difficult to state a definitive long-term outlook, and whether heart or kidney disease is present is considered one of the factors affecting quality of life.
Some individuals experience only mild developmental delay and slower-than-average growth, while others have accompanying heart or kidney abnormalities that require more careful management during the perinatal period and childhood. This difference is thought to stem from the extent of the deletion and which genes beyond FGFR2 and DOCK1 happen to be included.
In my own clinical practice, I am sometimes asked by families of children with rare chromosomal conditions like this one about what to expect for their child’s development. Because case data is still accumulating worldwide, the outlook is best built gradually, over time, in consultation with your child’s physician.
9. Support for Families, and Planning for a Future Child
The isolation that comes with a rare disease can feel significant, but several resources are available, including genetic counseling, patient support groups, and public consultation services.
It may be hard to find another family nearby dealing with the same condition. Even so, you can connect with other families affected by rare chromosomal conditions, and draw on the specialized support that genetic counseling provides. Leave the medical management to your doctors and therapy staff, and let your family’s role be simply celebrating your child’s small steps of progress together — that is what I always tell the families I see.
If you are interested in the relationship between NIPT and intellectual disability, our article on that topic may help. If you are concerned about microdeletions more broadly, our article on the risks associated with microscopic chromosomal changes is also worth a look.
If you are considering NIPT for a future pregnancy, how much microdeletion coverage a plan includes will affect which option is right for you. If you are not sure which plan fits your situation, try our Plan Finder. Phone consultations are also welcome — feel free to reach us at 0120-169-629.
Frequently Asked Questions
Are “10q26 deletion syndrome” and “distal 10q deletion syndrome” the same condition?
Yes, they refer to the same condition. “Distal 10q deletion syndrome” is the name used for 10q26 deletion syndrome in international databases such as GARD and Orphanet.
Is this the same condition as the “10q22-3q23-2 deletion syndrome” or “12q14 microdeletion syndrome” articles on this site?
No, these are different conditions. 10q22-3q23-2 deletion syndrome involves a different region near the middle of the same chromosome 10, while 12q14 microdeletion syndrome is an abnormality on chromosome 12, a different chromosome altogether. Because the location determines which genes and symptoms are involved, we cover each condition in its own separate article.
Can NIPT detect a deletion in the 10q26 region?
It is not usually covered by standard NIPT, and even expanded panels that screen for microdeletions rarely name this region specifically. Because NIPT is a non-definitive test, a suspected case must be confirmed with a definitive test such as amniocentesis.
Is this an inherited condition? Will it affect a future child?
Most cases arise from a spontaneous (de novo) change, in which case the recurrence risk for a future child is generally considered low. However, if one parent is an unaffected carrier of a balanced translocation, there is roughly a 50% chance the deletion could be passed on, so this should be confirmed through genetic counseling.
Do genital abnormalities always occur?
No, not always. The 2015 clinical comparison study mentioned above found that deletions limited to the more distal region (10q26.2) tend to show prominent genital abnormalities, while deletions that extend further into the more proximal region are more likely to also involve kidney and urinary tract abnormalities. Which symptoms tend to appear depends on the extent of the deletion.
What treatment options are available?
There is no cure that reverses the chromosomal deletion itself. Care centers on multidisciplinary support tailored to the individual’s symptoms, including medical management of heart or kidney disease, developmental therapy, hearing and vision care, and behavioral support.
Medical supervision: Dr. Hiroshi Oka — Director-in-Chief and Lab Director, Hiro Clinic (Fukumikai Medical Corporation). A graduate of Keio University School of Medicine, Dr. Oka holds a Ph.D. in Medicine and has passed the national medical licensing examinations of both Japan and the United States. He is one of the few physicians in Japan to hold laboratory director credentials. This article was prepared in line with Japan’s medical advertising guidelines, drawing on public and academic sources including GARD, Orphanet, and peer-reviewed medical literature. Reported frequencies and case counts vary between sources because so few cases have been documented; please consult your physician for decisions about diagnosis and treatment.
日本皮膚科学会 皮膚科専門医／日本医師会 産業医／東京衛生検査所 指導監督医
この記事は、 ヒロクリニックNIPTの編集・監修体制 にもとづき、資格を持つ医師が内容を確認しています。
